Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China
Yunpeng Yang(Sun Yat-sen University), Li Zhang(Peking University), Meizuo Zhong(Central South University), Wangjun Liao(Sun Yat-sen University), Xingsheng Hu(Capital Medical University), Hongxia Xu(Kunming University of Science and Technology), Jihua Zheng(Second Military Medical University), Nong Yang(Central South University), Yiping Zhang(Zhejiang Cancer Hospital), Kaican Cai(Nanfang Hospital), Lin Wu(Materials Systems (United States)), Jian Fang(Peking University), Wei Li(Jilin University), Hui Liu(Yantaishan Hospital), Dong Wang(Sun Yat-sen University), Jinfeng Li(Hebei Medical University), Xiaojian Liu(Central South University), Sheng Ye(Shanghai University), Xiaojia Wang(Wenzhou Medical University), Wei Zhong(Chinese Academy of Medical Sciences & Peking Union Medical College), Qiong Zhao(Zhejiang University), Gang Cheng(Chinese Academy of Medical Sciences & Peking Union Medical College), Li Jin(Sun Yat-sen University), Jianjin Huang(Second Affiliated Hospital of Zhejiang University), Quchang Ouyang(Hunan Cancer Hospital), Diansheng Zhong(Tianjin Medical University General Hospital), Nong Xu(First Affiliated Hospital Zhejiang University), Helong Zhang(Shanghai International Studies University)
Cited by 8
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Aristolochic acid and the etiology of endemic (Balkan) nephropathy
|Proceedings of the National Academy of Sciences|2007|598